In this article, we will be taking a look at the Top 10 Oncology Stocks to Buy Now.

The oncology market in the United States was estimated at  $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%. This growth can be mainly explained by the rising cancer rates and the higher expectations of personalized, more effective, and sophisticated treatment.

Targeted treatments and monoclonal antibodies remain the top sectors of the US oncology industry, with monoclonal antibodies accounting for about 30% of market sales in 2024. The Inflation Reduction Act’s Medicare drug-price negotiation provisions, which will take effect in 2026 for some expensive Part D medications like ibrutinib, are intended to reduce costs for patients and healthcare programs. This price adjustment is expected to make their products more affordable, but some manufacturers are reconsidering their investment policies, especially regarding post-approval studies and long-term research and development, due to the possible impact on future revenue streams.

The major trends affecting the US oncology sector include the growing trend of artificial intelligence that is set to achieve an accuracy rate of around 70%-80% in predicting patient response to immunotherapy in certain situations by 2026. Antibody-Drug Conjugates (ADCs) and Bi-specific T-cell Engagers (TCEs), which are called next-generation modalities, are improving therapeutic efficacy and decreasing toxicity. Furthermore, non-invasive biopsies (liquid biopsies based on circulating tumor DNA (ctDNA) are taking the place of the traditional biopsies as a disease monitoring technique.

Looking ahead, oncology is increasingly becoming molecularly defined into subsets, thus enabling clinicians to target particular mutations, including KRASG12D or HER2 low, instead of treating malignancies based entirely on organ site. There is an emerging trend towards therapeutic messenger RNA (mRNA) vaccines, which are currently undergoing late-stage clinical trials with the likelihood of approval in 2027-2029. The convergence of radiopharmaceuticals, protein degraders (PROTAC), and AI-driven diagnostics will be an important part of the United States oncology market in the near future and will offer more individualized and precision-based care.

With that being said, let’s now look at the top 10 oncology stocks.

Our Methodology

For our methodology, we focused on oncology stocks by screening exchange-traded funds (ETFs) such as CANC and CNCR. From these ETFs, we identified the top 10 stocks with the highest number of hedge fund holders as of Q3 2025, according to data from the Insider Monkey database. These stocks were then ranked in ascending order based on their number of hedge fund holdings.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

Here is our list of the top 10 oncology stocks to buy now.

10. Genmab A/S (NASDAQ:GMAB)

Number of Hedge Fund Holders: 20

Genmab A/S (NASDAQ:GMAB) is one of the best cancer stocks on our list.

TheFly reported on January 8 that Deutsche Bank raised its price target for GMAB to DKK 2,400 from DKK 2,000 and reiterated a Buy rating, reflecting analysts’ optimism about the company’s late-stage oncology pipeline.

Separately, a day earlier, on January 7, Genmab A/S (NASDAQ:GMAB) partnered with AI research company Anthropic to enhance its R&D capabilities using agentic AI powered by Claude models. While keeping human control, the AI will automate complicated data processing and document creation. The partnership is a move toward a more scalable, effective, and digitally enabled R&D process, according to Tahamtan Ahmadi, EVP and Chief Medical Officer.

Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and Epkinly.

9. Novartis AG (NYSE:NVS)

Number of Hedge Fund Holders: 33

Novartis AG (NYSE:NVS) is placed ninth on our list among the best cancer stocks.

TheFly reported on January 6 that Barclays upgraded NVS to Equal Weight from Underweight with a CHF 120 price target after a coverage transfer. Barclays noted a poor operational outlook for 2026 and stated that the company’s “fairly rich” pipeline is mostly reflected in valuation and faces competition.

In other news, Novartis AG (NYSE:NVS) unveiled a 35,000-square-foot RLT facility in Winter Park, Florida, on January 9. This is the company’s fourth U.S. location and a component of its $23 billion U.S. investment strategy. The facility handles specific, time-sensitive logistics and was built to support precision oncology treatments such as Pluvicto and Lutathera.

Novartis AG (NYSE:NVS) is a global biopharmaceutical leader with a robust oncology portfolio, including over 30 high-value therapies and a growing radioligand therapy (RLT) pipeline. The company invests heavily in precision oncology, advanced manufacturing, and targeted treatments like Pluvicto and Lutathera to address complex cancer needs worldwide.